Qiagen NV (XTER:QIA) Debt-to-Equity

: 0.40 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

Qiagen NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €560 Mil. Qiagen NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €845 Mil. Qiagen NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3,492 Mil. Qiagen NV's debt to equity for the quarter that ended in Dec. 2023 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Qiagen NV's Debt-to-Equity or its related term are showing as below:

XTER:QIA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.4 Med: 0.59 Max: 0.83
Current: 0.4

During the past 13 years, the highest Debt-to-Equity Ratio of Qiagen NV was 0.83. The lowest was 0.40. And the median was 0.59.

XTER:QIA's Debt-to-Equity is ranked worse than
60.41% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.24 vs XTER:QIA: 0.40

Qiagen NV Debt-to-Equity Historical Data

The historical data trend for Qiagen NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.68

0.70

0.63

0.54

0.40

Qiagen NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.54	0.53	0.52	0.40	0.40

Competitive Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qiagen NV Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Debt-to-Equity falls into.

Qiagen NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Qiagen NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(559.588	+	845.313)	/	3491.72
	=	0.40

Qiagen NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(559.588	+	845.313)	/	3491.72
	=	0.40

Qiagen NV (XTER:QIA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Qiagen NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV (XTER:QIA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (XTER:QIA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

QGEN:USA 1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Qiagen NV (XTER:QIA) Headlines

No Headlines